In a largely male-dominated Wall Street, where “old boys club” attitudes are still felt at all levels of the complex financial world, it is encouraging to see an increasing number of women in leadership positions who take the Street by a storm, coming from top universities such as the world-renowned Massachusetts Institute of Technology. Christiana Stamoulis is one of these women.

After graduating from MIT with two undergraduate degrees, including a Bachelor of Science in Economics and a Master degree in Finance (MBA) and four years in Management Consulting, Ms. Stamoulis has been in top investment banking firms in Wall Street since 2000. Currently, Ms. Stamoulis is a Managing Director in the Healthcare Group of the Investment Banking Division at New York-based Citigroup. Since 2006, she has driven the East Coast Life Sciences effort on behalf of Citigroup, serving as a lead coverage officer for US Large Cap Pharmaceutical and Large Cap Biotech companies. Ms. Stamoulis is personally responsible for a large part of the progress Citigroup has made in the building of the Company’s Life Sciences Investment Banking Group.

With over a decade of experience in the pharmaceutical and biotech industry, Christiana Stamoulis brings to the table her widely admired analytical skills and industry experience necessary to effect the successful culmination of several high-profile financial transactions. Ms. Stamoulis has acted as the Senior Advisor to a number of CEOs, CFOs, and board members on issues related to strategic and corporate finance decisions. As a member of the Citigroup team, she advised Bristol-Myers Squibb on its offer to acquire ImClone Systems. Christiana Stamoulis and the rest of the Citigroup team are also credited with advising Bristol Myers Squibb on the $4 billion sale of its ConvaTec business to Nordic Capital and Avista Capital.

Christiana Stamoulis built her investment-banking career at Goldman, Sachs & Co., where she remained until 2006 when she was recruited by Citigroup to help the Company expand its Life Sciences effort. She credits both her education at MIT and her investment banking experience at Goldman Sachs for her success as an investment banker. “I am an engineer at heart” she confesses when asked about her approach to different high-profile mergers and acquisitions deals and other financial transactions in which she has played a key role. “At MIT we learn how to think analytically, look at a problem from outside the box, be creative, and I was very fortunate that at Goldman this approach was also highly encouraged”. Asked about the position of women in Wall Street, she agrees that it is not always easy being a woman there but she adds “we know how to hold our own”.